Why it Matters
The House Energy and Commerce Subcommittee on Health convened last week for a hearing roundup latest on illicit drug policy — examining more than a dozen bills targeting fentanyl, xylazine, nitazenes, and other emerging threats. The Trump administration has made border security and drug interdiction central to its agenda, making this hearing broadly aligned with executive priorities. That said, tensions emerged over treatment policy, particularly a bill that would roll back an HHS rule expanding access to opioid use disorder medications.
The Big Picture
The hearing, titled "Policies to Protect Our Communities from Illicit Drug Threats," reviewed 13 separate pieces of legislation. The bills span enforcement, treatment, and scheduling — from the Combatting Illicit Xylazine Act to the STOP Nitazenes Act to the Stop Pills That Kill Act. The breadth of the legislative package reflects the continued evolution of the drug supply — as fentanyl has given way to polysubstance threats including xylazine, nitazenes, and tianeptine. One bill — H.R. 5629 — would nullify an HHS rule that expanded access to medications for opioid use disorder, drawing sharp disagreement among witnesses.
What They're Saying
The panel drew five witnesses representing law enforcement, public health, addiction medicine, treatment, and recovery advocacy — offering a wide range of perspectives on the hearing proceedings.
- Yngvild Olsen, MD, MPH, an addiction medicine physician, submitted written testimony focused on evidence-based treatment access.
- Nabarun Dasgupta, PhD, MPH, an epidemiologist, brought a research perspective on the changing drug supply.
- K. Fred Gingrich II, DVM offered a law enforcement and interdiction lens, per his testimony.
- Scott Oulton represented the treatment provider community, submitting testimony and supporting documents.
- Dennis Lemma brought a recovery community perspective, with witness testimony and multiple supporting documents.
The Legislative Package
The 13 bills under review represent one of the more comprehensive illicit drug legislative packages to move through committee in the 119th Congress. Key measures include:
- Tyler's Law (H.R. 2004) — specifics not detailed in available documents
- Fight Illicit Pill Presses Act (H.R. 5880) — targeting counterfeit pill manufacturing equipment
- Alternatives to PAIN Act (H.R. 1227) — focused on non-opioid pain management alternatives
- Destruction of Hazardous Imports Act (H.R. 2715) — addressing interdiction of dangerous imported substances
- ALERT Communities Act (H.R. 1561) — community-level response framework
- Prohibiting Tianeptine and Other Dangerous Products Act of 2026 (H.R. 7407) — scheduling of the so-called "gas station heroin"
- END 7-OH Act (H.R. 8000) and HERO Act (H.R. 7994) — additional scheduling and enforcement tools
- PRESS Act (H.R. 7184)
Political Stakes
The most contested item in the hearing proceedings was H.R. 5629, which would nullify the HHS rule on medications for opioid use disorder — except for its accreditation provisions. That rule expanded flexibility for prescribing buprenorphine and methadone. Witnesses like Olsen, an addiction medicine specialist, and Dasgupta, a public health researcher, are likely to have pushed back on rolling back those access provisions. The bill puts the committee in a difficult position: enforcement-focused members may support tighter controls, while public health advocates argue that treatment access saves lives.
Member statements were submitted by Rep. H. Morgan Griffith, Rep. Brett Guthrie, Rep. Diana DeGette, and Rep. Frank Pallone, Jr. The presence of Pallone and DeGette — senior Democrats — signals the minority is engaged on this issue.
The witness panel was balanced between enforcement and treatment perspectives. Gingrich's law enforcement background contrasts with Olsen's and Dasgupta's public health framing. That divide mirrors a long-running congressional debate: whether the drug crisis is primarily a supply problem requiring interdiction, or a health crisis requiring treatment infrastructure.
H.R. 5629's inclusion — a bill that would roll back treatment flexibility — is the sharpest expression of that tension in this package.
Lemma's recovery community perspective adds a third voice: those in recovery who may have views on both enforcement and treatment that don't map neatly onto either camp.
What's Next
Given the size of the package — 13 bills — some measures are likely to advance separately. Bills with broader bipartisan support, like those targeting xylazine and nitazenes, may move faster than the more contentious H.R. 5629. No floor votes have been scheduled based on available data. The fight over treatment access, not just enforcement, is where the real friction lies.
Access the Legis1 platform for comprehensive political news, data, and insights.